Abilify aripiprazole neurology data
The U.S. Department of Health and Human Service's Agency for Healthcare Research and Quality (AHRQ) released a draft comparative effectiveness review of off-label use of atypical antipsychotics showing that off-label use of Abilify aripiprazole, Zyprexa olanzapine, Seroquel quetiapine and Risperdal risperidone showed moderate or high evidence of efficacy for treating dementia, while Abilify, Seroquel and Risperdal were efficacious for treating depression. Seroquel showed moderate or high evidence of efficacy in treating anxiety and Risperdal in treating post-traumatic stress disorder, while both drugs were efficacious in treating obsessive compulsive disorder (OCD). The draft report did not find data to support off-label use of the 3 most recently FDA approved atypical antipsychotics - Saphris asenapine; Fanapt iloperidone; and Invega paliperidone. The agency also noted that there is insufficient data regarding efficacy, effectiveness and harms to determine what subset of the population would potentially benefit from off-label uses of atypical antipsychotics. ...